Patents by Inventor Kazuhide Inoue
Kazuhide Inoue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9115123Abstract: A P2X4 receptor antagonist such as paroxetine, a diazepinedione derivative having the following formula (IX) is used as an agent for preventing or treating zoster-associated pain in acute phase: wherein R1 is hydrogen, a C1-8 alkyl group, or the like; each of R2 and R3 is hydrogen, a C1-8 alkyl group, or the like; each of R4 and R5 is hydrogen or the like; and W is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring.Type: GrantFiled: November 2, 2011Date of Patent: August 25, 2015Assignee: Kyushu UniversityInventors: Kazuhide Inoue, Makoto Tsuda, Yuta Matsumura
-
Patent number: 8962613Abstract: A diazepine derivative having the following formula (III) or a pharmacologically acceptable salt thereof is used as A P2X4 receptor antagonist: wherein each of R21 and R22 is hydrogen, a C1-8 alkyl group or the like; R23 is hydrogen, a C1-8 alkyl group or the like; each of R24 and R25 is hydrogen, a C1-8 alkyl group or the like; R26 is hydrogen, a C1-8 alkyl group, a halogen atom, hydroxyl, nitro, cyano, phenyl optionally having one or more substituents, or a heterocyclic group optionally having one or more substituents or the like; and p is 0 or 1.Type: GrantFiled: July 13, 2011Date of Patent: February 24, 2015Assignee: Nippon Chemiphar Co., Ltd.Inventors: Shogo Sakuma, Masahiko Arai, Kunio Kobayashi, Yoshikazu Watanabe, Toshiyasu Imai, Kazuhide Inoue
-
Publication number: 20140357858Abstract: The present invention relates to a diazepine derivative represented by the following general formula (I) (in the formula, R1 and R2 represent hydrogen atom and the like, or R1 and R2 bind together to form a naphthalene ring and the like together with the benzene ring to which they bind, R3 and R4 represent hydrogen atom and the like, R5 represents hydrogen atom and the like, R6 and R7 represent hydrogen atom and the like, X represents C, CH or N, Y represents N, NH or C(?O), provided that when X is N, Y is not N or NH, and when X is C or CH, Y is not C(?O), Z represents oxygen atom or sulfur atom, A represents benzene ring and the like, B represents NHC(?O) and the like, D represents an atomic bond and the like, E represents an atomic bond and the like, G represents benzene which may be substituted and the like, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a P2X4 receptor antagonist.Type: ApplicationFiled: January 10, 2013Publication date: December 4, 2014Inventors: Masatoshi Ushioda, Kunio Kobayashi, Daisuke Saito, Shogo Sakuma, Toshiyasu Imai, Kazuhide Inoue
-
Publication number: 20140163013Abstract: A P2X4 receptor antagonist such as paroxetine, a diazepinedione derivative having the following formula (IX) is used as an agent for preventing or treating neuropathic pain associated with Guillain-Barré syndrome: wherein R1 is hydrogen, a C1-8 alkyl group, or the like; each of R2 and R3 is hydrogen, a C1-8 alkyl group, or the like; each of R4 and R5 is hydrogen or the like; and W is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring.Type: ApplicationFiled: May 25, 2012Publication date: June 12, 2014Inventors: Toshiyasu Imai, Toru Kawasaki, Toru Ogawa, Kazuhide Inoue
-
Publication number: 20140148599Abstract: A P2X4 receptor antagonist such as paroxetine, a diazepinedione derivative having the following formula (IX) is used as an agent for preventing or treating zoster-associated pain in acute phase: wherein R1 is hydrogen, a C1-8 alkyl group, or the like; each of R2 and R3 is hydrogen, a C1-8 alkyl group, or the like; each of R4 and R5 is hydrogen or the like; and W is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring.Type: ApplicationFiled: November 2, 2011Publication date: May 29, 2014Applicants: NIPPON CHEMIPHAR CO., LTD., KYUSHU UNIVERSITYInventors: Kazuhide Inoue, Makoto Tsuda, Yuta Matsumura
-
Patent number: 8680110Abstract: A compound having the following formula (II) or a pharmacologically acceptable salt thereof is used as a P2X4 receptor antagonist: wherein each of R11 and R12 is hydrogen, C1-8 alkyl or the like; R13 is hydrogen, C1-8 alkyl or the like; R14 is C1-8 alkoxy, hydroxyl, cyano, a heterocyclic group optionally having a substituent or the like; and the condensed ring consisting of W1 and the neighboring benzene ring is naphthalene ring or the like.Type: GrantFiled: July 27, 2011Date of Patent: March 25, 2014Assignee: Nippon Chemiphar Co., Ltd.Inventors: Masatoshi Ushioda, Shogo Sakuma, Toshiyasu Imai, Kazuhide Inoue
-
Patent number: 8673915Abstract: A compound having the following formula (II) or a pharmacologically acceptable salt thereof is used as a P2X4 receptor antagonist: wherein each of R11 and R12 is hydrogen, C1-8 alkyl or the like; R13 is hydrogen, C1-8 alkyl or the like; R14 is hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 alkyl having 1-3 halogens, C1-8 hydroxyalkyl, halogen, hydroxyl, nitro, cyano, amino, C1-8 alkylamino, benzenesulfonylamino optionally having a substituent, a heterocyclic group optionally having a substituent or the like; and the condensed ring consisting of W1 and the neighboring benzene ring is naphthalene, tetrahydronaphthalene, or indan ring.Type: GrantFiled: July 27, 2011Date of Patent: March 18, 2014Assignee: Nippon Chemiphar Co., Ltd.Inventors: Masatoshi Ushioda, Shogo Sakuma, Atsushi Tendo, Toshiyasu Imai, Kazuhide Inoue
-
Publication number: 20130184459Abstract: A compound having the following formula (II) or a pharmacologically acceptable salt thereof is used as a P2X4 receptor antagonist: wherein each of R11 and R12 is hydrogen, C1-8 alkyl or the like; R13 is hydrogen, C1-8 alkyl or the like; R14 is C1-8 alkoxy, hydroxyl, cyano, a heterocyclic group optionally having a substituent or the like; and the condensed ring consisting of W1 and the neighboring benzene ring is naphthalene ring or the like.Type: ApplicationFiled: July 27, 2011Publication date: July 18, 2013Applicant: NIPPON CHEMIPHAR CO., LTD.Inventors: Masatoshi Ushioda, Shogo Sakuma, Toshiyasu Imai, Kazuhide Inoue
-
Publication number: 20130178625Abstract: A compound having the following formula (II) or a pharmacologically acceptable salt thereof is used as a P2X4 receptor antagonist: wherein each of R11 and R12 is hydrogen, C1-8 alkyl or the like; R13 is hydrogen, C1-8 alkyl or the like; R14 is hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 alkyl having 1-3 halogens, C1-8 hydroxyalkyl, halogen, hydroxyl, nitro, cyano, amino, C1-8 alkylamino, benzenesulfonylamino optionally having a substituent, a heterocyclic group optionally having a substituent or the like; and the condensed ring consisting of W1 and the neighboring benzene ring is naphthalene, tetrahydronaphthalene, or indan ring.Type: ApplicationFiled: July 27, 2011Publication date: July 11, 2013Applicant: NIPPON CHEMIPHAR CO., LTD.Inventors: Masatoshi Ushioda, Shogo Sakuma, Atsushi Tendo, Toshiyasu Imai, Kazuhide Inoue
-
Publication number: 20130172550Abstract: A diazepine derivative having the following formula (III) or a pharmacologically acceptable salt thereof is used as A P2X4 receptor antagonist: wherein each of R21 and R22 is hydrogen, a C1-8 alkyl group or the like; R23 is hydrogen, a C1-8 alkyl group or the like; each of R24 and R25 is hydrogen, a C1-8 alkyl group or the like; R26 is hydrogen, a C1-8 alkyl group, a halogen atom, hydroxyl, nitro, cyano, phenyl optionally having one or more substituents, or a heterocyclic group optionally having one or more substituents or the like; and p is 0 or 1.Type: ApplicationFiled: July 13, 2011Publication date: July 4, 2013Applicant: Nippon Chemiphar Co., Ltd.Inventors: Shogo Sakuma, Masahiko Arai, Kunio Kobayashi, Yoshikazu Watanabe, Toshiyasu Imai, Kazuhide Inoue
-
Patent number: 8470814Abstract: A diazepinedione derivative represented by the formula (I) or a pharmacologically acceptable salt thereof is used as a P2X4 receptor antagonist: wherein R1 represents a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, or the like, R2 and R3 represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, a halogen atom, or the like, R4 and R5 represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, or the like, and W represents tetrazole or the like.Type: GrantFiled: February 15, 2010Date of Patent: June 25, 2013Assignee: Nippon Chemiphar Co., Ltd.Inventors: Shogo Sakuma, Toshihiro Takahashi, Masatoshi Ushioda, Toshiyasu Imai, Kazuhide Inoue
-
Publication number: 20120116073Abstract: A compound having the following formula (II) or its pharmacologically acceptable salt is used as a P2X4 receptor antagonist: in which R11 represents hydrogen or an alkyl group having 1-8 carbon atoms; R21 represents an alkyl group having 1-8 carbon atoms, an alkoxy group having 1-8 carbon atoms, an alkyl group having 1-8 carbon atoms and having 1-3 halogen substituents, or hydroxyl; and R31 is hydrogen or a halogen atom.Type: ApplicationFiled: January 20, 2012Publication date: May 10, 2012Applicant: NIPPON CHEMIPHAR COL, LTD.Inventors: Shogo SAKUMA, Tsuyoshi Endo, Toshiyasu Imai, Noriko Kanakubo, Masahiko Arai, Toshihiro Takahashi, Kenji Hirate, Takako Hirate, Tomio Yamakawa, Makoto Tsuda, Kazuhide Inoue
-
Publication number: 20110319610Abstract: A diazepinedione derivative represented by the formula (I) or a pharmacologically acceptable salt thereof is used as a P2X4 receptor antagonist: wherein R1 represents a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, or the like, R2 and R3 represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, a halogen atom, or the like, R4 and R5 represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, or the like, and W represents tetrazole or the like.Type: ApplicationFiled: February 15, 2010Publication date: December 29, 2011Applicant: NIPPON CHEMIPHAR CO., LTD.Inventors: Shogo Sakuma, Toshihiro Takahashi, Masatoshi Ushioda, Toshiyasu Imai, Kazuhide Inoue
-
Publication number: 20110092703Abstract: A P2X4 receptor antagonist is a compound represented by the formula (I) or a pharmacologically acceptable salt thereof, which is used as a preventive or therapeutic agent for neuropathic pains: Wherein B is aryl or the like that can have a substituent; Y is C1-5 alkylene that can have a double bond; Z is O, S or the like; each of R1, R2 and R3 independently is hydrogen, C1-8 alkyl or the like; R4 is hydrogen, C1-8 alkyl or the like; each of P and Q independently is hydrogen, halogen, C1-8 alkyl or the like; W is C1-8 alkyl or the like; and each of n and m independently is 1 or 2.Type: ApplicationFiled: August 8, 2008Publication date: April 21, 2011Applicant: NIPPON CHEMIPHAR CO., LTD.Inventors: Shogo Sakuma, Tsuyoshi Endo, Noriko Kanakubo, Masahiko Arai, Toshihiro Takahashi, Toshiyasu Imai, Kumiko Taguchi, Eriko Nakata, Nobutaka Mochiduki, Masatoshi Ushioda, Makoto Tsuda, Kazuhide Inoue
-
Publication number: 20100256123Abstract: A compound having the following formula (II) or its pharmacologically acceptable salt is used as a P2X4 receptor antagonist: in which R11 represents hydrogen or an alkyl group having 1-8 carbon atoms; R21 represents an alkyl group having 1-8 carbon atoms, an alkoxy group having 1-8 carbon atoms, an alkyl group having 1-8 carbon atoms and having 1-3 halogen substituents, or hydroxyl; and R31 is hydrogen or a halogen atom.Type: ApplicationFiled: August 24, 2007Publication date: October 7, 2010Applicant: NIPPON CHEMIPHAR CO., LTD.Inventors: Shogo Sakuma, Tsuyoshi Endo, Toshiyasu Imai, Noriko Kanakubo, Masahiko Arai, Toshihiro Takahashi, Tomio Yamakawa, Makoto Tsuda, Kazuhide Inoue, Kenji Hirate, Takako Hirate
-
Publication number: 20050074819Abstract: The present invention relates to a screening method for a compound useful for treatment of neuropathic pain, and therapy for the treatment of neuropathic pain. The screening method comprises determining inhibitory activity on the action of P2X4 receptor or inhibitory activity on the activation of microglia, of test compounds. The pharmaceutical composition and the therapy employ a P2X4 receptor inhibitor or a microglial activation-inhibitor as active ingredient.Type: ApplicationFiled: October 1, 2003Publication date: April 7, 2005Inventors: Kazuhide Inoue, Makoto Tsuda, Schuichi Koizumi, Shinichi Kohsaka